Therapy persistence by drug regimen and age after 4 years of follow-up
| Age group | Monotherapy* | Fixed combination* | Free combination* |
|---|---|---|---|
| ≤50 (n=2133) | 34.0% (31.8% to 36.3%) | 38.5% (31.9% to 45.4%) | 57.0% (48.2% to 65.5%) |
| >50–60 (n=1686) | 42.3% (39.7% to 45.0%) | 39.3% (32.6% to 46.4%) | 54.8% (46.0% to 63.4%) |
| >60–70 (n=1615) | 43.6% (40.8% to 46.3%) | 42.9% (35.8% to 50.3%) | 58.6% (50.2% to 66.7%) |
| >70–80 (n=1775) | 43.0% (40.4% to 45.6%) | 38.2% (31.0% to 45.8%) | 57.7% (49.5% to 65.6%) |
| >80 (n=555) | 42.8% (38.2% to 47.5%) | 34.0% (21.5% to 48.3%) | 58.8% (44.2% to 72.4%) |
| All | 40.3% (39.2% to 41.6%) | 39.8% (36.5% to 43.2%) | 56.4% (52.5% to 60.2%) |
*Percentage and 95% CIs are reported.